What types of oral anticoagulants have evidence of effectiveness in renal infarction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 8, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Los anticoagulantes orales directos (DOAC) como apixaban y rivaroxaban tienen evidencia de efectividad en el tratamiento del infarto renal, y se prefieren debido a su farmacocinética predecible y la falta de necesidad de monitoreo regular. Estos medicamentos trabajan previniendo la formación y extensión de coágulos, permitiendo que el sistema fibrinolítico natural del cuerpo disuelva los coágulos existentes. Algunos de los DOAC que se pueden considerar para el tratamiento del infarto renal incluyen:

  • Apixaban
  • Rivaroxaban
  • Edoxaban
  • Dabigatran La elección entre estos agentes debe considerar la función renal del paciente, comorbilidades, medicamentos concomitantes y riesgo de sangrado 1, 2. Es importante tener en cuenta que la dosis de estos medicamentos puede necesitar ajustes según la función renal, edad y peso del paciente. Además, la anticoagulación se continúa típicamente durante al menos 3-6 meses, aunque pueden ser necesarias duraciones más largas dependiendo de la causa subyacente del infarto 3, 4. En general, los DOAC se consideran una opción viable para el tratamiento del infarto renal, especialmente en pacientes con enfermedad renal crónica, ya que han demostrado ser efectivos en la prevención de eventos tromboembólicos y hemorrágicos 5. Sin embargo, es fundamental evaluar cuidadosamente los beneficios y riesgos de la anticoagulación en cada paciente y ajustar la dosis y el tratamiento según sea necesario.

References

3
Research

Direct Oral Anticoagulants in End-Stage Renal Disease.

Seminars in thrombosis and hemostasis, 2018

4
Research

The use of direct oral anticoagulants in chronic kidney disease.

British journal of haematology, 2018

Related Questions

How many days should Xarelto (rivaroxaban) be discontinued before a scheduled dental appointment for local anesthesia in an 82-year-old male?
What is the optimal management for an 85-year-old female with atrial fibrillation, bradycardia, and mildly elevated blood pressure, currently on atenolol and lisinopril?
What are the recommended anticoagulants (AntiCoagulants) for patients requiring anticoagulation therapy, including those with impaired renal function (Renal Impairment)?
What are the classifications, mechanisms, and dosing of anticoagulants, including Direct Oral Anticoagulants (DOACs) like apixaban (apixaban) and rivaroxaban (rivaroxaban), vitamin K antagonists like warfarin (warfarin), and heparins, and how are they monitored?
What is the cause of bilateral leg edema in a 75-year-old male with a history of deep vein thrombosis (DVT) in 2017, currently on Xarelto (rivaroxaban), without heart failure or kidney disease?
What does it mean to have high free kappa (kappa light chains) and high free lambda (lambda light chains)?
What's the next step for a 45-year-old woman with major depressive disorder, previously treated with citalopram (escitalopram) and fluoxetine, now showing only a modest response to venlafaxine 15 mg/day?
What's the next step for a patient with treatment-resistant depression who hasn't responded to Venlafaxine (Effexor) 225 mg/day and Abilify (Aripiprazole) 10 mg/day?
What are the elements to study as etiology of renal infarction?
What's the next step for a patient with MRSA who showed no improvement after treatments with Bactrim DS (Sulfamethoxazole/Trimethoprim), Keflex (Cephalexin), and Linezolid?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question